Non-thyroidal illness syndrome predicts poor prognosis in hepatocellular carcinoma patients treated with atezolizumab and bevacizumab.

Cancer Immunol Immunother · 2026 · PMC12847513 · PMID 41591568

Europe PMC DOI

hedged sentence

0.0730

closest p · 1.5× alpha

0.0730

boldest claim

The sentences

only marginally significantP = 0.073so close (0.05 < p ≤ 0.1)

In the adjusted analysis, the association between thyroid AEs and PFS became only marginally significant (adjusted HR, 0.370; 95% CI, 0.125–1.099; P = 0.073), while older age was not no longer a significant risk factor (Table 2 ).

also in 5,076 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.